CD274 and neoplasm: Additionally, current biomarker strategies to assess patients’ response to different types of immunotherapies, including the tumor neoantigen landscape, mutational burden, PD-L1 expression, and tumor-infiltrating lymphocyte landscape [132,133,134] in tumor and/or liquid biopsies [135], may enable accurate patient selection and improve the efficacy and safety of immunotherapy during the IPP.